ClinicalTrials.gg
RecruitingNCT07224438Updated Jul 13, 2026

Kisspeptin Administration Subcutaneously to Patients With Hypothalamic Amenorrhea

A Phase 2 interventional study of kisspeptin 112-121 in Hypothalamic Amenorrhea and Hypogonadotropic Hypogonadism, sponsored by Stephanie B. Seminara, MD. Recruiting at 1 site in United States. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-07-13.

Sponsored by Stephanie B. Seminara, MD · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 185 studies in Hypogonadism with a site in United States — 12 open to participants now, 15 under way, 2 of them phase 3. Hypogonadism · United States.

Planned enrollment
116th of 154
20 · median 45
Started
2025
with 4 others
Phase 2
54 of 185
4 open now
Primary completion
2030-05
later than 11 of 13 live
Registered
184th of 185
by date
Lead sponsor
6 of 185
Stephanie B. Seminara, MD

Among the 185 studies in Hypogonadism with a site in United States, this one is the 116th largest by planned enrollment of the 154 interventional ones that give a count, is one of 5 that started in 2025, is one of 54 in phase 2, reaches primary completion later than 11 of the 13 other live ones, and was the 184th registered.

Hypogonadism

320 studies on the registry are indexed under Hypogonadism; 39 are open to participants now.

Browse Hypogonadism studies →

Open to participants now

12 of the 185 studies in Hypogonadism with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 24 Hypogonadism studies recruiting now, 9 (38%) set no upper age limit and 12 (50%) stop at 75 or younger; 6 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 45 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 185 studies in Hypogonadism with a site in United States, or all of them as a file.
02

Study summary

The goal of this study is to see whether kisspeptin, a naturally occurring hormone, can stimulate the release of other reproductive hormones in women with hypothalamic amenorrhea (HA). The investigators are also examining whether kisspeptin can help women release eggs from their ovaries. Kisspeptin will be administered subcutaneously (SC) for two weeks in a pulsatile fashion. Ultrasound monitoring of ovarian follicular growth and frequent blood sampling (every 10 minutes for up to two hours) will be performed to assess the physiologic response to kisspeptin over time.

Read the detailed description

Assignment: All study subjects will undergo the same interventions.

Delivery of Interventions:

  • The subject will undergo a review of their medical history, physical exam, and screening laboratories.
  • A pelvic ultrasound will be performed to assess baseline follicular size.
  • A pump will be placed to administer pulsatile SC kisspeptin for two weeks.
  • During the course of kisspeptin administration, subjects will
  • Undergo q10 min blood sampling (approximately 4 sessions, 2 hours each)
  • Undergo pelvic ultrasounds (approximately 4 sessions)
  • Optional q10 min sampling up to 10 hours may take place before and after the course of kisspeptin
03

Conditions studied

  • Hypothalamic Amenorrhea
  • Hypogonadotropic Hypogonadism

Browse trials for

Keywords

  • hypothalamic amenorrhea
  • hypogonadotropic hypogonadism
  • kisspeptin
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female
  • Ages 18-45 years
  • Acquired HH (hypothalamic amenorrhea, aka functional hypogonadotropic hypogonadism)
  • Normal blood pressure (systolic BP \< 140 mm Hg, diastolic \< 90 mm Hg)
  • no less than 0.5 g/dL below the lower limit of the reference range for normal women
  • Negative serum hCG pregnancy test
  • No current or recent use of a medication (including hormonal replacement) that, in the opinion of a study investigator, can modulate the reproductive axis OR willing to complete an appropriate for that particular medication and its method of administration
  • If applicable, willing to use methods (as approved by a study medical professional) during the entire study and for one month after the last dose of study drug

Exclusion criteria

Exclusion Criteria:

  • Any condition (medical, mental, or behavioral) that, in the opinion of a study investigator, would likely interfere with participation in/completion of the protocol
  • Excessive alcohol consumption (>10 drinks/week)
  • Active use of illicit drugs
  • Pregnant
  • Trying to become pregnant during protocol participation
  • Breast feeding
  • History of any of the following: bilateral oophorectomy (ovaries were removed), breast cancer, thromboembolic disease, coronary artery disease, stroke, thrombophilic disorders, or undiagnosed abnormal genital bleeding
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Kisspeptin pump

    SC administration of kisspeptin for two weeks (pulsatile)

    Drug: kisspeptin 112-121

Interventions

06

What researchers measure

Primary outcomes

  1. Change of luteinizing hormone (LH) pulse amplitude

    Difference in LH amplitude on the first day of kisspeptin administration vs the last day of kisspeptin administration

    Time frame: 2 weeks

Other outcomes

  1. The proportion of participants that achieve development of a mature follicle or show evidence of ovulation

    Mature follicle achievement is defined as evidence of a follicle with maximum diameter ≥18 mm. Evidence of ovulation is defined as detection of a corpus luteum on ultrasound in combination with elevated progesterone level.

    Time frame: 2 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for May 2030, 53 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2025
First posted
Nov 4, 2025
StartActual
Dec 9, 2025
Primary completionEst.
May 2030
CompletionEst.
May 2030
Last update
Jul 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07224438
Lead sponsor
Stephanie B. Seminara, MD
Responsible party
Stephanie B. Seminara, MD (Chief, Reproductive Endocrine Unit; Professor of Medicine, Harvard Medical School; Director, MGH Harvard Center for Reproductive Medicine, Massachusetts General Hospital) — Sponsor-investigator
First posted
Nov 4, 2025
Start date
Dec 9, 2025
Primary completion
May 2030 (estimated)
Completion
May 2030 (estimated)
Last update
Jul 13, 2026

Study contacts

Study Coordinator
Contact
MGHKisspeptinResearch@partners.org
617-643-2308

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: KISS1 protein, human

Start the discussion